Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Grandy who wrote (193)	1/20/1997 11:51:00 PM
From: billkirn	of 6136

Glaxo Wellcome announced this on Jan 9th. The 24-week, open-label, Phase II clinical trial is designed to test the tolerability, pharmacokinetics and antiviral efficacy of double HIV protease regimens including 141W94/VX-478 plus either saquinavir (Roche), indinavir (Merck) or nelfinavir (Agouron). A fourth group treated with VX-478 plus Glaxo Wellcome's Retrovir(R) (AZT) and Epivir(R) (3TC) will provide a comparison arm for the trial. The study is expected to enroll approximately 48 HIV-positive adults. The entry criteria for the study include CD4 cells (greater than or equal to) 200/mm3 and plasma HIV RNA (greater than or equal to) 20,000 copies per mL. My sense is that the killer combo will be the Agouron -Vertex. I believe these protease inhibitors have the least side effects for any of the AIDs drugs. If this works, treatment costs will be much lower and patients can expect minimal side effects.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next